These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30873942)

  • 21. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
    Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.
    Tanaka Y; Takeuchi T; Haaland D; Hall S; Inanc N; Li Z; Xavier RM; Cara C; Tilt N; Taylor PC
    Int J Rheum Dis; 2023 Jul; 26(7):1248-1259. PubMed ID: 37195063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V; Mease P; Burmester GR; Nikaï E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
    Arthritis Res Ther; 2009; 11(6):R170. PubMed ID: 19909548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial.
    Pfeil A; Nussbaum A; Renz DM; Hoffmann T; Malich A; Franz M; Oelzner P; Wolf G; Böttcher J
    Arthritis Res Ther; 2020 Oct; 22(1):229. PubMed ID: 33023661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
    Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
    Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L; Lapadula G; Mathieu A
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
    Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek HP; Innes A; Strand V
    Ann Rheum Dis; 2009 Jun; 68(6):805-11. PubMed ID: 19015206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study.
    Bessette L; Haraoui B; Chow A; Fortin I; Dixit S; Khraishi M; Haaland D; Elmoufti S; Staelens F; Bogatyreva I; Syrotuik J; Shaikh S
    Ther Adv Musculoskelet Dis; 2019; 11():1759720X19831151. PubMed ID: 30858896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies.
    Takeuchi T; Yamamoto K; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2015 Jan; 25(1):11-20. PubMed ID: 24842476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
    Pope J; Rampakakis E; Vaillancourt J; Bessette L; Lazovskis J; Haraoui B; Sampalis JS
    Rheumatology (Oxford); 2020 Jul; 59(7):1522-1528. PubMed ID: 31628486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
    Weinblatt ME; Fleischmann R; Huizinga TW; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham CO; Duncan B; Goel N; Davies OR; Dougados M
    Rheumatology (Oxford); 2012 Dec; 51(12):2204-14. PubMed ID: 22923753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of periarticular bone loss is associated with clinical remission and ACR70-Response in rheumatoid arthritis.
    Pfeil A; Nussbaum A; Renz DM; Jung C; Oelzner P; Malich A; Wolf G; Böttcher J
    Rheumatol Int; 2019 Apr; 39(4):637-645. PubMed ID: 30569216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol.
    Curtis JR; Churchill M; Kivitz A; Samad A; Gauer L; Gervitz L; Koetse W; Melin J; Yazici Y
    Arthritis Rheumatol; 2015 Dec; 67(12):3104-12. PubMed ID: 26316013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial.
    Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Bjørner JB; Hetland ML
    Arthritis Rheumatol; 2019 Dec; 71(12):1997-2004. PubMed ID: 31268624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: Interim analysis of post-marketing surveillance].
    Kameda H; Nishida K; Nannki T; Watanabe A; Oshima Y; Momohara S
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(3):196-205. PubMed ID: 28747607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
    Pope J; Bingham CO; Fleischmann RM; Dougados M; Massarotti EM; Wollenhaupt J; Duncan B; Coteur G; Weinblatt ME
    Arthritis Res Ther; 2015 Nov; 17():343. PubMed ID: 26614481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
    Weinblatt ME; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; VanLunen B; Ecoffet C; Cioffi C; Emery P
    Arthritis Rheumatol; 2017 Oct; 69(10):1937-1948. PubMed ID: 28666080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.